Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Feature Articles

Our features section includes quick-to-read updates from ‘VJToday’ on the latest data, as well as presentations and slides from specialist meetings, and multi-media features that take a deeper dive into a topic. Explore more below!

Filter content by

FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia

On October 2, 2026, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib for adult patients with previously untreated chronic…

Read More

Beyond gene therapy: can mitapivat reshape everyday SCD care?

The therapeutic landscape for sickle cell disease (SCD) continues to evolve rapidly, with gene therapies offering a potentially curative treatment…

Read More

Etentamig demonstrates significantly improved ORR and PFS in R/R multiple myeloma: CERVINO topline results

On September 3, 2026, topline results from the CERVINO trial (NCT06158841) were announced, demonstrating significantly improved efficacy and safety outcomes…

Read More

FDA approves ropeginterferon alfa-2b for adult patients with essential thrombocythemia

On August 31, 2026, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft for adult patients with essential thrombocythemia…

Read More

FDA approves rusfertide as a first-in-class therapy for the treatment of polycythemia vera

On August 28, 2026, the U.S. Food and Drug Administration (FDA) granted approval to rusfertide for the treatment of adult…

Read More

FDA approves iberdomide for the treatment of patients with R/R multiple myeloma

On August 13, 2026, the U.S. Food and Drug Administration (FDA) granted approval to iberdomide combined with daratumumab and hyaluronidase-fihj…

Read More

Top abstracts from the VJHemOnc Post-EHA Lymphoma Highlights webinar 2026

We have highlighted five key abstracts from the Post-EHA 2026 Lymphoma Highlights webinar with the potential to influence the management…

Read More

Top abstracts from the VJHemOnc Post-EHA AML Highlights webinar 2026

Read about five abstracts from the Post-EHA 2026 AML Highlights webinar that showcase advances in the treatment of acute myeloid…

Read More

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals